75. クッシング病 Cushing disease Clinical trials / Disease details


臨床試験数 : 205 薬物数 : 176 - (DrugBank : 45) / 標的遺伝子数 : 61 - 標的パスウェイ数 : 127

  
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2021-006184-19-BG
(EUCTR)
22/06/202231/05/2022Study of SPI-62 in Patients with Adrenocorticotropic Hormone-dependent Cushing’s SyndromeSPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing’s Syndrome Cushing’s Syndrome
MedDRA version: 20.1;Level: PT;Classification code 10035109;Term: Pituitary-dependent Cushing's syndrome;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
Product Name: SPI-62
Product Code: SPI-62
INN or Proposed INN: Not applicable
Other descriptive name: 11-ß-hydroxysteroid dehydrogenase type 1
Sparrow Pharmaceuticals, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
26Phase 2United States;Romania;Bulgaria
2NCT05436639
(ClinicalTrials.gov)
June 9, 202223/6/2022SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal TumorSPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal TumorAutonomous Cortisol Secretion (ACS);ACTH-Independent Cushing Syndrome;ACTH-Independent Adrenal Cushing Syndrome, SomaticDrug: SPI-62 dose1;Drug: SPI-62 dose 2;Drug: SPI-62 dose 3;Drug: SPI-62 dose 4;Drug: PlaceboSparrow PharmaceuticalsNULLRecruiting18 YearsN/AAll150Phase 2United States;Bulgaria;France;Romania;United Kingdom;Germany;Italy
3NCT05307328
(ClinicalTrials.gov)
March 1, 202223/3/2022SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's SyndromeSPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's SyndromeCushing's Syndrome I;Cushing Disease Due to Increased ACTH Secretion;Cortisol Excess;Cortisol; Hypersecretion;Cortisol Overproduction;Ectopic ACTH SecretionDrug: SPI-62;Drug: PlaceboSparrow PharmaceuticalsNULLRecruiting18 YearsN/AAll26Phase 2Romania;Bulgaria;United States